<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:xhtml="http://www.w3.org/1999/xhtml">
  <url>
    <loc>https://pharminsider.com/</loc>
    <changefreq>hourly</changefreq>
    <priority>1.0</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/" />
  </url>
  <url>
    <loc>https://pharminsider.com/search</loc>
    <changefreq>monthly</changefreq>
    <priority>0.3</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/search" />
  </url>
  <url>
    <loc>https://pharminsider.com/privacy</loc>
    <changefreq>monthly</changefreq>
    <priority>0.3</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/privacy" />
  </url>
  <url>
    <loc>https://pharminsider.com/terms</loc>
    <changefreq>monthly</changefreq>
    <priority>0.3</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/terms" />
  </url>
  <url>
    <loc>https://pharminsider.com/cookies</loc>
    <changefreq>monthly</changefreq>
    <priority>0.3</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/cookies" />
  </url>
  <url>
    <loc>https://pharminsider.com/disclaimer</loc>
    <changefreq>monthly</changefreq>
    <priority>0.3</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/disclaimer" />
  </url>
  <url>
    <loc>https://pharminsider.com/editorial</loc>
    <changefreq>monthly</changefreq>
    <priority>0.3</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/editorial" />
  </url>
  <url>
    <loc>https://pharminsider.com/advertising</loc>
    <changefreq>monthly</changefreq>
    <priority>0.3</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/advertising" />
  </url>
  <url>
    <loc>https://pharminsider.com/contacts</loc>
    <changefreq>monthly</changefreq>
    <priority>0.3</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/contacts" />
  </url>
  <url>
    <loc>https://pharminsider.com/about</loc>
    <changefreq>monthly</changefreq>
    <priority>0.3</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/about" />
  </url>
  <url>
    <loc>https://pharminsider.com/dmca</loc>
    <changefreq>monthly</changefreq>
    <priority>0.3</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/dmca" />
  </url>
  <url>
    <loc>https://pharminsider.com/categories/pipeline-trials</loc>
    <changefreq>hourly</changefreq>
    <priority>0.8</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/categories/pipeline-trials" />
  </url>
  <url>
    <loc>https://pharminsider.com/categories/regulation-fda</loc>
    <changefreq>hourly</changefreq>
    <priority>0.8</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/categories/regulation-fda" />
  </url>
  <url>
    <loc>https://pharminsider.com/categories/generics-biosimilars</loc>
    <changefreq>hourly</changefreq>
    <priority>0.8</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/categories/generics-biosimilars" />
  </url>
  <url>
    <loc>https://pharminsider.com/categories/manufacturing</loc>
    <changefreq>hourly</changefreq>
    <priority>0.8</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/categories/manufacturing" />
  </url>
  <url>
    <loc>https://pharminsider.com/categories/deals-business</loc>
    <changefreq>hourly</changefreq>
    <priority>0.8</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/categories/deals-business" />
  </url>
  <url>
    <loc>https://pharminsider.com/categories/research-discovery</loc>
    <changefreq>hourly</changefreq>
    <priority>0.8</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/categories/research-discovery" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/ciplas-new-york-plant-gets-fda-no-action-classification</loc>
    <lastmod>2026-11-19T13:40:13.074Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/ciplas-new-york-plant-gets-fda-no-action-classification" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-approves-perioperative-imfinzi-padcev-regimen-in-bladder-cancer</loc>
    <lastmod>2026-11-19T13:40:13.074Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-approves-perioperative-imfinzi-padcev-regimen-in-bladder-cancer" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-rejects-ivonescimab-in-summits-egfr-nsclc-application</loc>
    <lastmod>2026-11-19T13:40:13.074Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-rejects-ivonescimab-in-summits-egfr-nsclc-application" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/nelkarmi-wins-accelerated-fda-approval-gsk-shares-hold-at-gbx1-871</loc>
    <lastmod>2026-11-19T13:40:13.074Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/nelkarmi-wins-accelerated-fda-approval-gsk-shares-hold-at-gbx1-871" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-approves-gsks-nelkarmi-for-pretreated-alk-positive-lung-cancer</loc>
    <lastmod>2026-11-19T13:40:13.074Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-approves-gsks-nelkarmi-for-pretreated-alk-positive-lung-cancer" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-clears-cosentyx-for-polymyalgia-rheumatica-roche-s-wilserdly-for-esr1-mutate</loc>
    <lastmod>2026-11-19T07:40:59.026Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-clears-cosentyx-for-polymyalgia-rheumatica-roche-s-wilserdly-for-esr1-mutate" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/terumo-bct-automates-engineered-til-production-with-quantum-flex</loc>
    <lastmod>2026-11-19T06:53:11.065Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/terumo-bct-automates-engineered-til-production-with-quantum-flex" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/alcohol-cuts-anti-pd-1-efficacy-roughly-50-in-mouse-cancer-models</loc>
    <lastmod>2026-11-19T06:53:11.065Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/alcohol-cuts-anti-pd-1-efficacy-roughly-50-in-mouse-cancer-models" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-clears-gsk-s-nelkarmi-second-asset-from-10-6b-nuvalent-deal</loc>
    <lastmod>2026-11-19T06:53:11.065Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-clears-gsk-s-nelkarmi-second-asset-from-10-6b-nuvalent-deal" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-agrees-200-patient-phase-3-design-for-rec-4881-in-fap</loc>
    <lastmod>2026-11-19T05:42:53.323Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-agrees-200-patient-phase-3-design-for-rec-4881-in-fap" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-clears-roche-s-wilserdly-for-advanced-breast-cancer</loc>
    <lastmod>2026-11-19T05:42:53.323Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-clears-roche-s-wilserdly-for-advanced-breast-cancer" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-moves-to-withdraw-approval-of-flolipid-liquid-simvastatin</loc>
    <lastmod>2026-11-19T05:42:53.323Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-moves-to-withdraw-approval-of-flolipid-liquid-simvastatin" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-grants-gsk-accelerated-approval-for-alk-inhibitor-nelkarmi</loc>
    <lastmod>2026-11-19T05:42:53.323Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-grants-gsk-accelerated-approval-for-alk-inhibitor-nelkarmi" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-clears-cosentyx-for-polymyalgia-rheumatica-11th-us-indication</loc>
    <lastmod>2026-11-19T05:42:53.323Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-clears-cosentyx-for-polymyalgia-rheumatica-11th-us-indication" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-hands-cipla-s-invagen-new-york-plant-no-action-indicated-status</loc>
    <lastmod>2026-11-19T04:23:10.362Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-hands-cipla-s-invagen-new-york-plant-no-action-indicated-status" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-clinical-pharmacology-mapp-takes-effect-with-four-review-areas</loc>
    <lastmod>2026-11-19T04:23:10.362Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-clinical-pharmacology-mapp-takes-effect-with-four-review-areas" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-clears-two-tubeless-insulin-systems-medtronic-buys-contego-for-380m</loc>
    <lastmod>2026-11-19T04:23:10.362Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-clears-two-tubeless-insulin-systems-medtronic-buys-contego-for-380m" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-rejects-ivonescimab-j-j-bets-3-3b-on-eye-biotech-ollin</loc>
    <lastmod>2026-11-19T04:23:10.362Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-rejects-ivonescimab-j-j-bets-3-3b-on-eye-biotech-ollin" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/marrow-therapeutics-raises-173m-for-bone-marrow-targeted-therapies</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/marrow-therapeutics-raises-173m-for-bone-marrow-targeted-therapies" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/flagship-puts-100m-into-first-non-u-s-company-creation-lab-in-london</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/flagship-puts-100m-into-first-non-u-s-company-creation-lab-in-london" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/ensol-bio-science-targets-kosdaq-transfer-on-fda-fast-track-and-obesity-licensin</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/ensol-bio-science-targets-kosdaq-transfer-on-fda-fast-track-and-obesity-licensin" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/immunobrain-s-anti-pd-l1-antibody-cuts-alzheimer-s-damage-biomarkers-in-phase-ib</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/immunobrain-s-anti-pd-l1-antibody-cuts-alzheimer-s-damage-biomarkers-in-phase-ib" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-opens-its-approval-files-to-world-regulators-with-grdp</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-opens-its-approval-files-to-world-regulators-with-grdp" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/oyster-therapeutics-lands-60m-to-take-protein-degraders-into-the-brain</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/oyster-therapeutics-lands-60m-to-take-protein-degraders-into-the-brain" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/pfizer-secures-up-to-1-5b-for-berobenatide-trials</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/pfizer-secures-up-to-1-5b-for-berobenatide-trials" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/bora-books-437m-cdmo-contracts-defers-25-batches-on-fda-upgrades</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/bora-books-437m-cdmo-contracts-defers-25-batches-on-fda-upgrades" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/pfizer-s-bourla-chinese-drugmakers-will-be-my-main-rivals</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/pfizer-s-bourla-chinese-drugmakers-will-be-my-main-rivals" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/trump-withdraws-overton-widening-fda-leadership-gap-for-sponsors</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/trump-withdraws-overton-widening-fda-leadership-gap-for-sponsors" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-approves-pebrilzo-but-settlement-delays-biocons-u-s-launch</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-approves-pebrilzo-but-settlement-delays-biocons-u-s-launch" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/nih-to-replace-disease-based-trial-funding-with-five-trial-type-nofos</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/nih-to-replace-disease-based-trial-funding-with-five-trial-type-nofos" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/antibacterial-pipeline-shrinks-from-97-to-90-and-ai-resistance-tools-inherit-bad</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/antibacterial-pipeline-shrinks-from-97-to-90-and-ai-resistance-tools-inherit-bad" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/eu-regulators-weigh-streamlining-combination-product-reviews</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/eu-regulators-weigh-streamlining-combination-product-reviews" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/pfizer-pays-330m-for-three-starna-in-vivo-car-t-programs</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/pfizer-pays-330m-for-three-starna-in-vivo-car-t-programs" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/folr1-adc-resensitizes-colorectal-tumors-to-anti-pd-1-in-mice</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/folr1-adc-resensitizes-colorectal-tumors-to-anti-pd-1-in-mice" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/help-votes-wednesday-on-overton-as-fda-shelves-cnpv</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/help-votes-wednesday-on-overton-as-fda-shelves-cnpv" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/windward-bio-raises-225-million-in-ipo-and-placement</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/windward-bio-raises-225-million-in-ipo-and-placement" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/j-j-pays-2-2-billion-for-ollin-mounting-direct-challenge-to-roche-s-vabysmo</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/j-j-pays-2-2-billion-for-ollin-mounting-direct-challenge-to-roche-s-vabysmo" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/glenmark-files-us-fda-ind-for-three-target-oncology-drug-isb-2301</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/glenmark-files-us-fda-ind-for-three-target-oncology-drug-isb-2301" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-rejects-ivonescimab-greenlights-roche-s-wilserdly-oncology-wave</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-rejects-ivonescimab-greenlights-roche-s-wilserdly-oncology-wave" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-rejects-china-developed-ivonescimab-on-overall-survival-grounds</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-rejects-china-developed-ivonescimab-on-overall-survival-grounds" />
  </url>
  <url>
    <loc>https://pharminsider.com/articles/fda-grants-gsks-neladalkib-accelerated-approval-for-alk-lung-cancer</loc>
    <lastmod>2026-11-19T03:48:12.231Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <xhtml:link rel="alternate" hreflang="en" href="https://pharminsider.com/articles/fda-grants-gsks-neladalkib-accelerated-approval-for-alk-lung-cancer" />
  </url>
</urlset>
